Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EMTRICITABINE\TENOFOVIR DISOPROXIL vs ENASIDENIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

EMTRICITABINE\TENOFOVIR DISOPROXIL vs ENASIDENIB: Safety Overview

Metric EMTRICITABINE\TENOFOVIR DISOPROXIL ENASIDENIB
Total FAERS Reports 39,362 3,704
Deaths Reported 1,254 967
Death Rate 3.2% 26.1%
Hospitalizations 4,560 1,143
Average Patient Age 46.1 yrs 70.3 yrs
% Female Patients 29.8% 43.6%
FDA Approval Date N/A Aug 1, 2017
Manufacturer N/A Celgene Corporation
Route N/A ORAL
Marketing Status N/A Prescription